Style | Citing Format |
---|---|
MLA | Ayubi E, Safiri S. "Serum Interleukin-6 and Survivin Levels Predict Clinical Response to Etanercept Treatment in Patients With Established Rheumatoid Arthritis: Methodological Issues." Modern Rheumatology, vol. 28, no. 2, 2018, pp. 380-. |
APA | Ayubi E, Safiri S (2018). Serum Interleukin-6 and Survivin Levels Predict Clinical Response to Etanercept Treatment in Patients With Established Rheumatoid Arthritis: Methodological Issues. Modern Rheumatology, 28(2), 380-. |
Chicago | Ayubi E, Safiri S. "Serum Interleukin-6 and Survivin Levels Predict Clinical Response to Etanercept Treatment in Patients With Established Rheumatoid Arthritis: Methodological Issues." Modern Rheumatology 28, no. 2 (2018): 380-. |
Harvard | Ayubi E, Safiri S (2018) 'Serum Interleukin-6 and Survivin Levels Predict Clinical Response to Etanercept Treatment in Patients With Established Rheumatoid Arthritis: Methodological Issues', Modern Rheumatology, 28(2), pp. 380-. |
Vancouver | Ayubi E, Safiri S. Serum Interleukin-6 and Survivin Levels Predict Clinical Response to Etanercept Treatment in Patients With Established Rheumatoid Arthritis: Methodological Issues. Modern Rheumatology. 2018;28(2):380-. |
BibTex | @article{ author = {Ayubi E and Safiri S}, title = {Serum Interleukin-6 and Survivin Levels Predict Clinical Response to Etanercept Treatment in Patients With Established Rheumatoid Arthritis: Methodological Issues}, journal = {Modern Rheumatology}, volume = {28}, number = {2}, pages = {380-}, year = {2018} } |
RIS | TY - JOUR AU - Ayubi E AU - Safiri S TI - Serum Interleukin-6 and Survivin Levels Predict Clinical Response to Etanercept Treatment in Patients With Established Rheumatoid Arthritis: Methodological Issues JO - Modern Rheumatology VL - 28 IS - 2 SP - 380 EP - PY - 2018 ER - |